Seshu Tyagarajan

CIK: 0001923794

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)6 (60.0%)

Position reduction

Option Exercises (M)1 (10.0%)

Derivative conversions

Awards (A)3 (30.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CADL

Candel Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (10 total)

CADL
Candel Therapeutics, Inc.
Aug 17, 2026
Sale(S)
Direct
7K shares at avg. $12.00$84K
CADL
Candel Therapeutics, Inc.
Jun 29, 2026
Sale(S)
Direct
7K shares at avg. $10.02$70K
CADL
Candel Therapeutics, Inc.
Jan 26, 2026
Award(A)
Stock Option (Right to Buy)
Direct
154K shares-
CADL
Candel Therapeutics, Inc.
Jun 25, 2025
Award(A)
Direct
5.4K shares at avg. $4.67$25K
CADL
Candel Therapeutics, Inc.
Mar 17, 2025
Sale(S)
Direct
31.3K shares at avg. $8.82$276K
CADL
Candel Therapeutics, Inc.
Mar 17, 2025
Exercise(M)
Direct
20K shares at avg. $1.29$26K
CADL
Candel Therapeutics, Inc.
Feb 12, 2025
Award(A)
Stock Option (Right to Buy)
Direct
65K shares-
CADL
Candel Therapeutics, Inc.
Jan 15, 2025
Sale(S)
Direct
14.3K shares at avg. $7.22$103K
CADL
Candel Therapeutics, Inc.
Jan 8, 2025
Sale(S)
Direct
14.5K shares at avg. $8.22$120K
CADL
Candel Therapeutics, Inc.
Nov 29, 2024
Sale(S)
Direct
20.4K shares at avg. $4.56$93K

		Type	Shares	Price		Ownership
Aug 17, 2026	CADL Candel Therapeutics, Inc.	Sale(S)	7,000	$12.00	$84,000	Direct
Jun 29, 2026	CADL Candel Therapeutics, Inc.	Sale(S)	7,000	$10.02	$70,151	Direct
Jan 26, 2026	CADL Candel Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	154,000	-	-	Direct
Jun 25, 2025	CADL Candel Therapeutics, Inc.	Award(A)	5,353	$4.67	$24,999	Direct
Mar 17, 2025	CADL Candel Therapeutics, Inc.	Sale(S)	31,278	$8.82	$275,947	Direct
Mar 17, 2025	CADL Candel Therapeutics, Inc.	Exercise(M)	20,000	$1.29	$25,800	Direct
Feb 12, 2025	CADL Candel Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	65,000	-	-	Direct
Jan 15, 2025	CADL Candel Therapeutics, Inc.	Sale(S)	14,322	$7.22	$103,476	Direct
Jan 8, 2025	CADL Candel Therapeutics, Inc.	Sale(S)	14,545	$8.22	$119,534	Direct
Nov 29, 2024	CADL Candel Therapeutics, Inc.	Sale(S)	20,392	$4.56	$92,898	Direct

1-10 of 10 transactions

About Tyagarajan Seshu

Tyagarajan Seshu (SEC CIK 0001923794) files insider reports with the SEC as Chief Technology Officer of Candel Therapeutics, Inc. (CADL).

Signal8 holds 10 ownership filings by Tyagarajan Seshu, all Form 4s, filed between Dec 3, 2024 and Aug 19, 2026. Those filings report 10 transactions, from Nov 29, 2024 to Aug 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Tyagarajan Seshu's filings is in NEEDHAM, MA.

Recent filings by Tyagarajan Seshu

Aug 17, 2026: Open-market sale of CADL shares (Form 4, code S).
Jun 29, 2026: Open-market sale of CADL shares (Form 4, code S).
Jan 26, 2026: Grant or award of CADL derivative securities (Form 4, code A).
Jun 25, 2025: Grant or award of CADL shares (Form 4, code A).
Mar 17, 2025: Open-market sale of CADL shares (Form 4, code S).

Other insiders filing for Candel Therapeutics, Inc. (CADL)

Loggia Nicoletta, Director
PAPA JOSEPH C, Director
Manning Paul B, Director
Tak Paul Peter, Chief Executive Officer
Zimmermann Martine, Director
Sims Mark E., Chief Commercial Officer

How to read Form 4 transaction codes